SPEAKER: We have to realize that PCSK9 inhibitors not only lower LDL cholesterol, but they lower Lipoprotein(a). And Lipoprotein(a) is an important risk factor for a myocardial infarction. We know this from the emerging risk factors collaboration.

We also know that in subgroup analysis from FOURIER and ODYSSEY outcomes, those individuals with cardiovascular disease who have a higher Lp(a) have a higher event rate. And they have a disproportionate benefit from PCSK9 inhibitors. Statins, ezetimibe, have no effect on Lp(a), but the PCSK9 inhibitors do.